FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167368130> ?p ?o ?g. }

• W2167368130 endingPage "2250" @default.
• W2167368130 startingPage "2240" @default.
• W2167368130 abstract "To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.This was an open, phase I, escalating multiple-dose tolerability and pharmacokinetic trial. ZD1839 was administered once daily for 14 consecutive days followed by 14 days off treatment. Dose escalation started at 50 mg/d and continued to 925 mg or until consistent dose-limiting toxicity (DLT) was observed.Sixty-four patients were entered at eight dose levels. The most frequent dose-related grade 1 and 2 adverse events were an acne-like (or folliculitis) rash, nausea, and diarrhea. Three of nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events were uncommon. Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 hours (range, 37 to 65). Four of 16 patients with non-small-cell lung cancer (NSCLC) had objective partial responses observed from ZD1839 300 to 700 mg/d. Overall, 16 patients remained on study for > or = 3 months, with seven of these patients (five with NSCLC, including three of the patients with partial response) remaining on study for > or = 6 months.ZD1839 was well tolerated, with DLT observed at a dose well above that at which antitumor activity was seen. Pharmacokinetic analysis confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation. Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839." @default.
• W2167368130 created "2016-06-24" @default.
• W2167368130 creator A5000660231 @default.
• W2167368130 creator A5001187394 @default.
• W2167368130 creator A5002037553 @default.
• W2167368130 creator A5004559185 @default.
• W2167368130 creator A5011905014 @default.
• W2167368130 creator A5029965393 @default.
• W2167368130 creator A5035278067 @default.
• W2167368130 creator A5039791495 @default.
• W2167368130 creator A5047743996 @default.
• W2167368130 creator A5055792960 @default.
• W2167368130 creator A5063080412 @default.
• W2167368130 creator A5081130122 @default.
• W2167368130 creator A5089314722 @default.
• W2167368130 date "2002-05-01" @default.
• W2167368130 modified "2023-10-14" @default.
• W2167368130 title "ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial" @default.
• W2167368130 cites W1954313480 @default.
• W2167368130 cites W1995634658 @default.
• W2167368130 cites W2021996848 @default.
• W2167368130 cites W2040264246 @default.
• W2167368130 cites W2058992264 @default.
• W2167368130 cites W2064047613 @default.
• W2167368130 cites W2087415667 @default.
• W2167368130 cites W2088597803 @default.
• W2167368130 cites W2135836172 @default.
• W2167368130 cites W2189849157 @default.
• W2167368130 cites W27838513 @default.
• W2167368130 cites W4240064739 @default.
• W2167368130 cites W4249359548 @default.
• W2167368130 doi "https://doi.org/10.1200/jco.2002.10.112" @default.
• W2167368130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11980995" @default.
• W2167368130 hasPublicationYear "2002" @default.
• W2167368130 type Work @default.
• W2167368130 sameAs 2167368130 @default.
• W2167368130 citedByCount "725" @default.
• W2167368130 countsByYear W21673681302012 @default.
• W2167368130 countsByYear W21673681302013 @default.
• W2167368130 countsByYear W21673681302014 @default.
• W2167368130 countsByYear W21673681302015 @default.
• W2167368130 countsByYear W21673681302016 @default.
• W2167368130 countsByYear W21673681302017 @default.
• W2167368130 countsByYear W21673681302018 @default.
• W2167368130 countsByYear W21673681302019 @default.
• W2167368130 countsByYear W21673681302020 @default.
• W2167368130 countsByYear W21673681302021 @default.
• W2167368130 countsByYear W21673681302022 @default.
• W2167368130 countsByYear W21673681302023 @default.
• W2167368130 crossrefType "journal-article" @default.
• W2167368130 hasAuthorship W2167368130A5000660231 @default.
• W2167368130 hasAuthorship W2167368130A5001187394 @default.
• W2167368130 hasAuthorship W2167368130A5002037553 @default.
• W2167368130 hasAuthorship W2167368130A5004559185 @default.
• W2167368130 hasAuthorship W2167368130A5011905014 @default.
• W2167368130 hasAuthorship W2167368130A5029965393 @default.
• W2167368130 hasAuthorship W2167368130A5035278067 @default.
• W2167368130 hasAuthorship W2167368130A5039791495 @default.
• W2167368130 hasAuthorship W2167368130A5047743996 @default.
• W2167368130 hasAuthorship W2167368130A5055792960 @default.
• W2167368130 hasAuthorship W2167368130A5063080412 @default.
• W2167368130 hasAuthorship W2167368130A5081130122 @default.
• W2167368130 hasAuthorship W2167368130A5089314722 @default.
• W2167368130 hasConcept C112705442 @default.
• W2167368130 hasConcept C121608353 @default.
• W2167368130 hasConcept C126322002 @default.
• W2167368130 hasConcept C143998085 @default.
• W2167368130 hasConcept C197934379 @default.
• W2167368130 hasConcept C2778375690 @default.
• W2167368130 hasConcept C2778496288 @default.
• W2167368130 hasConcept C2778570526 @default.
• W2167368130 hasConcept C2779438470 @default.
• W2167368130 hasConcept C2780580376 @default.
• W2167368130 hasConcept C29730261 @default.
• W2167368130 hasConcept C71924100 @default.
• W2167368130 hasConcept C90924648 @default.
• W2167368130 hasConcept C98274493 @default.
• W2167368130 hasConceptScore W2167368130C112705442 @default.
• W2167368130 hasConceptScore W2167368130C121608353 @default.
• W2167368130 hasConceptScore W2167368130C126322002 @default.
• W2167368130 hasConceptScore W2167368130C143998085 @default.
• W2167368130 hasConceptScore W2167368130C197934379 @default.
• W2167368130 hasConceptScore W2167368130C2778375690 @default.
• W2167368130 hasConceptScore W2167368130C2778496288 @default.
• W2167368130 hasConceptScore W2167368130C2778570526 @default.
• W2167368130 hasConceptScore W2167368130C2779438470 @default.
• W2167368130 hasConceptScore W2167368130C2780580376 @default.
• W2167368130 hasConceptScore W2167368130C29730261 @default.
• W2167368130 hasConceptScore W2167368130C71924100 @default.
• W2167368130 hasConceptScore W2167368130C90924648 @default.
• W2167368130 hasConceptScore W2167368130C98274493 @default.
• W2167368130 hasIssue "9" @default.
• W2167368130 hasLocation W21673681301 @default.
• W2167368130 hasLocation W21673681302 @default.
• W2167368130 hasOpenAccess W2167368130 @default.
• W2167368130 hasPrimaryLocation W21673681301 @default.
• W2167368130 hasRelatedWork W139966500 @default.
• W2167368130 hasRelatedWork W2028182958 @default.

• next